# Depression and Anxiety in Older Adults

## Introduction

Late-life depression and anxiety are among the most significant yet most frequently overlooked conditions in geriatric medicine. Major depressive disorder affects 2 to 5 percent of community-dwelling elderly, while clinically significant depressive symptoms below the threshold for formal MDD diagnosis affect an additional 10 to 15 percent. In institutional settings, the prevalence rises dramatically, with 25 to 50 percent of long-term care residents affected. Specific medical events substantially increase depression risk, with 30 to 40 percent of post-stroke patients and 20 to 30 percent of post-myocardial infarction patients developing clinically significant depression.

Late-life depression is underdiagnosed, with approximately 50 percent of cases missed in primary care, and undertreated even when identified. The consequences of untreated depression in the elderly are severe and wide-ranging: functional decline, cognitive impairment, doubled mortality risk, suicide, increased healthcare utilization, and amplified caregiver burden. Anxiety disorders affect 7 to 14 percent of older adults, frequently coexist with depression (with 50 percent comorbidity), and are equally undertreated. A particularly alarming statistic is that elderly white males have the highest suicide rate of any demographic group, with rates 3 to 4 times the national average in men aged 85 and older, underscoring the lethal potential of unrecognized and untreated depression in this population.

## Clinical Presentation of Late-Life Depression

### Differences from Younger Adults

The clinical presentation of depression in older adults differs substantially from that in younger adults, and failure to recognize these differences accounts for much of the diagnostic gap. Somatic complaints predominate in geriatric depression, with patients presenting with fatigue, pain, insomnia, appetite changes, weight loss, constipation, and psychomotor retardation. Elderly patients are less likely to volunteer feelings of sadness or to endorse "feeling depressed" and may actively deny mood symptoms when questioned directly. Instead, they are more likely to manifest anhedonia, apathy, social withdrawal, cognitive complaints (the so-called "pseudodementia"), irritability, and anxiety.

The overlap between depressive symptoms and medical comorbidities further obscures the diagnosis. Fatigue may be attributed to heart failure, weight loss to cancer, insomnia to nocturia, and cognitive slowing to dementia, when in each case depression may be the primary or a major contributing cause. The concept of "depression without sadness" captures a common geriatric phenotype in which the cardinal emotional symptom of depression is absent or minimally expressed while the behavioral and somatic manifestations dominate the clinical picture.

### Subtypes

Late-life depression encompasses several clinical subtypes with distinct presentations and treatment implications. Major depressive disorder, meeting full DSM-5 criteria of 5 or more symptoms for 2 or more weeks, represents the most severe form. Persistent depressive disorder (dysthymia), defined by depressed mood on more days than not for 2 years or longer, produces chronic low-grade suffering that may be normalized by both the patient and clinician. Subsyndromal or minor depression, featuring clinically significant symptoms that do not meet full MDD criteria, is common in the elderly and carries meaningful risk of progression to MDD.

Vascular depression, a subtype of late-onset depression associated with cerebrovascular disease and white matter hyperintensities on neuroimaging, is characterized by executive dysfunction, apathy more than sadness, and a relatively poor response to antidepressant pharmacotherapy. Depression with psychotic features, manifesting as nihilistic, guilty, somatic, or paranoid delusions or hallucinations, requires combination treatment with an antipsychotic and antidepressant or electroconvulsive therapy. Bereavement-related depression may be triggered by the grief process, and clinicians must distinguish normal grief from complicated or prolonged grief disorder, now recognized in the DSM-5-TR as a distinct diagnostic entity.

### Depression vs. Dementia ("Pseudodementia")

Differentiating depressive cognitive impairment from dementia is a common and clinically important challenge. Depressive pseudodementia characteristically features rapid onset of cognitive symptoms, subjective memory complaints that exceed the objective deficits found on formal testing, patients who complain prominently about their cognitive problems ("I can't remember anything"), attention and concentration impairments that are more prominent than memory deficits, frequent "don't know" answers on cognitive testing, and performance that improves with encouragement and structure. In contrast, dementia typically presents with insidious onset, objective deficits that exceed the patient's subjective concerns, minimization or denial of cognitive problems, near-miss answers on testing, and progressive, irreversible decline.

A critical caveat is that depression and dementia frequently coexist, with 30 to 50 percent of patients with dementia having comorbid depression. Furthermore, depression in the elderly may itself be a prodrome of dementia, doubling the risk of subsequent dementia diagnosis. This bidirectional relationship means that successful treatment of depression with cognitive improvement does not eliminate the need for longitudinal cognitive monitoring.

## Screening and Diagnosis

### Screening Tools

The PHQ-9, a 9-item questionnaire scored from 0 to 27, is widely used and well-validated in elderly populations, with a score of 10 or above suggesting moderate depression. The Geriatric Depression Scale offers a screening instrument specifically designed for the elderly population. The GDS-15, a 15-item yes/no format, with a score of 5 or above suggesting depression and 10 or above suggesting moderate-to-severe depression, has the important advantage of avoiding somatic symptom confounding by not including questions about sleep, appetite, weight, or concentration, symptoms that are highly prevalent in the elderly regardless of mood. The GDS is not validated in patients with moderate-to-severe dementia, who require observational assessment tools. The Cornell Scale for Depression in Dementia is a clinician-administered instrument incorporating caregiver input that is validated for use in patients with dementia, with a score of 8 or above suggesting depression. The PHQ-2, an ultra-brief 2-item screen addressing anhedonia and depressed mood, with a score of 3 or above triggering a full PHQ-9, offers a time-efficient initial screen with a sensitivity of 91 percent and specificity of 67 percent.

### Suicide Risk Assessment

Direct assessment of suicide risk is essential in every elderly patient with depression. Clinicians should ask explicitly, "Have you been thinking about hurting yourself or that life is not worth living?" Risk factors for suicide in the elderly include male sex, white race, living alone, widowed or divorced marital status, chronic pain, functional limitations, medical illness, previous suicide attempt, substance use, and access to firearms. Elderly individuals use more lethal means than younger adults, with firearms being the most common method in the United States. They make fewer attempts but have a substantially higher completion rate. Protective factors include social connectedness, religious or spiritual engagement, sense of purpose, and access to mental health care. The Columbia Suicide Severity Rating Scale provides a structured framework for comprehensive suicide risk assessment.

<image>A comparison diagnostic chart distinguishing late-life depression from dementia and normal aging. Create a three-column table with rows comparing key features. Column headers: "Normal Aging," "Depression (Pseudodementia)," and "Dementia." Row comparisons: Onset (gradual vs. relatively rapid vs. insidious), Self-reported cognitive problems (occasional forgetfulness vs. exaggerated complaints "I can't remember anything" vs. minimized or denied), Testing performance (normal with effort vs. inconsistent, improves with structure, "don't know" answers vs. near-miss answers, progressive impairment), Mood (variable, adjusts to circumstances vs. persistently low, anhedonia, hopelessness vs. variable, may include apathy without sadness), Attention/concentration (mildly reduced vs. significantly impaired vs. variable by type), Course (stable vs. may improve with treatment vs. progressive decline), and Functional impact (minimal vs. disproportionate to cognitive findings vs. proportional to cognitive severity). Use color coding: green for normal aging, yellow for depression, orange for dementia. Include a note at the bottom: "Depression and dementia frequently COEXIST — 30-50% of dementia patients have comorbid depression."</image>

## Management of Depression

### Non-Pharmacological Interventions

Non-pharmacological interventions form a critical component of depression treatment in the elderly and may be used as monotherapy for mild depression or combined with medication for moderate-to-severe disease. Psychotherapy is considered first-line treatment and has strong evidence across several modalities. Cognitive behavioral therapy carries the strongest evidence base, addressing negative thought patterns and maladaptive cognitive schemas; it is effective in elderly patients with good cognitive function and can be adapted for those with mild cognitive impairment. Problem-solving therapy focuses on practical problem-solving skills and is particularly effective in elderly patients with medical comorbidity and executive dysfunction. Interpersonal therapy addresses grief, role transitions, and interpersonal conflicts, making it well-suited to the losses and social changes that characterize late life. Behavioral activation increases engagement in valued activities through structured scheduling and is simpler to implement than full CBT, making it effective for elderly patients with low motivation.

Exercise has demonstrated antidepressant efficacy comparable to sertraline in the SMILE trial, with moderate aerobic exercise at 150 minutes per week providing meaningful improvement in depressive symptoms alongside benefits for sleep, cognition, and physical function. Social prescribing addresses the isolation that frequently accompanies and perpetuates depression in the elderly, with referrals to community programs, senior centers, volunteer opportunities, and peer support groups.

### Pharmacological Treatment

| Screening Tool | Items | Scoring | Threshold | Best Use |
|---------------|-------|---------|-----------|----------|
| PHQ-2 | 2 items (anhedonia + depressed mood) | 0–6 | ≥3 triggers full PHQ-9 | Ultra-brief screen; sensitivity 91% |
| PHQ-9 | 9 items | 0–27 | ≥10: moderate depression | Well-validated in elderly |
| GDS-15 | 15 yes/no items | 0–15 | ≥5: suggests depression; ≥10: moderate-severe | Avoids somatic confounding; designed for elderly |
| Cornell Scale (CSDD) | Clinician-administered + caregiver | 0–38 | ≥8: depression | Validated in dementia |
| C-SSRS | Structured interview | Severity scale | Any positive response | Suicide risk assessment |

#### SSRIs — First-Line

Selective serotonin reuptake inhibitors are the first-line pharmacological treatment for late-life depression. Sertraline, initiated at 25 mg with a target dose of 50 to 100 mg, offers the advantages of few drug interactions and good tolerability. Escitalopram, started at 5 mg with a target of 10 mg (the maximum recommended dose for patients aged 65 and older due to FDA concerns about QTc prolongation), is the most selective SSRI. Citalopram, started at 10 mg with a target of 10 to 20 mg (maximum 20 mg in patients aged 65 and older due to FDA QTc warning at higher doses), is another well-tolerated option.

Paroxetine should be avoided in the elderly due to its anticholinergic properties (designated in the Beers Criteria as potentially inappropriate), its potent CYP2D6 inhibition creating drug interaction risk, its association with weight gain, and its withdrawal syndrome upon discontinuation. Fluoxetine should similarly be avoided due to its very long half-life (the active metabolite norfluoxetine has a half-life of 4 to 16 days) and its extensive cytochrome P450 interactions.

| Antidepressant | Starting Dose | Target Dose | Advantages in Elderly | Key Concerns |
|---------------|--------------|-------------|----------------------|--------------|
| Sertraline | 25 mg | 50–100 mg | Few drug interactions; well-tolerated | Hyponatremia; GI effects |
| Escitalopram | 5 mg | 10 mg (max in ≥65) | Most selective SSRI | QTc prolongation (FDA max 20 mg) |
| Duloxetine | 30 mg | 60 mg | Dual benefit: depression + pain | Avoid if CrCl <30; nausea |
| Mirtazapine | 7.5 mg | 15–30 mg | Sedating; appetite stimulation | Weight gain; useful when insomnia + anorexia coexist |
| Bupropion XL | 150 mg | 300 mg | Activating; no sexual dysfunction; no weight gain | Lowers seizure threshold; good for apathy |
| Venlafaxine XR | 37.5 mg | 75–225 mg | Dual mechanism | Monitor BP (dose-dependent hypertension) |
| **AVOID: Paroxetine** | — | — | — | **Anticholinergic (Beers); CYP2D6 inhibitor; weight gain** |
| **AVOID: Fluoxetine** | — | — | — | **Very long half-life; extensive CYP interactions** |

SSRI side effects of particular concern in the elderly include hyponatremia from SIADH, which should be monitored by checking serum sodium at 2 to 4 weeks after initiation or dose change, especially in patients taking concurrent diuretics. Falls risk increases with an odds ratio of 1.7. Sexual dysfunction and increased bleeding risk, particularly with concurrent anticoagulant or antiplatelet therapy, are additional considerations. The time to therapeutic response is 4 to 6 weeks but may extend to 8 to 12 weeks in elderly patients. Treatment should continue for at least 12 months after achieving remission for a first depressive episode and indefinitely for recurrent episodes.

#### SNRIs

Duloxetine at 30 to 60 mg offers the dual benefit of treating both depression and chronic pain conditions including diabetic neuropathy and musculoskeletal pain; it should be avoided when creatinine clearance falls below 30 mL/min. Venlafaxine extended-release at 37.5 to 225 mg provides combined serotonergic and noradrenergic effects at higher doses but requires blood pressure monitoring due to dose-dependent hypertension. Desvenlafaxine at 50 mg offers fewer drug interactions and requires no dose titration.

#### Other Antidepressants

Mirtazapine at 7.5 to 30 mg at bedtime is sedating at lower doses and promotes weight gain and appetite stimulation, properties that make it uniquely useful when insomnia and poor appetite coexist with depression. It has minimal anticholinergic effects and does not cause sexual dysfunction. Bupropion at 150 to 300 mg in the XL formulation is activating, does not cause sexual dysfunction or weight gain, and is particularly appropriate for apathy-predominant depression. It lowers the seizure threshold and should be avoided in patients with seizure history or eating disorders. Nortriptyline, a secondary tricyclic antidepressant at 10 to 75 mg at bedtime, is effective but carries anticholinergic burden and should be reserved for patients who have failed SSRIs and SNRIs, with ECG monitoring for cardiac conduction effects. Vortioxetine at 5 to 20 mg is a multimodal serotonergic agent that may improve cognitive function in depression, as suggested by the CONNECT study. Nausea is common, and while data specifically in elderly populations are limited, the agent shows promise.

#### Treatment-Resistant Depression

Treatment-resistant depression, defined as failure to respond to two or more adequate antidepressant trials, requires escalation to augmentation, combination, switching, or procedural interventions. Lithium augmentation at 300 to 600 mg, targeting a serum level of 0.4 to 0.6 mEq/L in the elderly, has evidence supporting its efficacy in augmenting SSRIs. The narrow therapeutic window mandates careful monitoring of renal and thyroid function and attention to dehydration risk. Aripiprazole augmentation at 2 to 5 mg is FDA-approved for MDD augmentation, with monitoring for extrapyramidal symptoms, akathisia, and metabolic effects.

Electroconvulsive therapy is the most effective treatment for severe depression, achieving remission rates of 60 to 80 percent. It is particularly indicated for psychotic depression, catatonia, suicidal ideation with imminent risk, treatment-resistant depression, and refusal to eat or drink. ECT is safe in elderly patients, including those with cardiac disease, dementia, and advanced age, when performed with modern brief-pulse technique and appropriate muscle relaxation and anesthesia. Side effects include transient confusion and retrograde and anterograde amnesia, which are usually temporary and can be minimized by right unilateral electrode placement. Maintenance ECT with monthly sessions prevents relapse after a successful acute course.

Transcranial magnetic stimulation is FDA-approved and non-invasive, with fewer cognitive side effects than ECT, though data specifically in elderly populations are limited. Esketamine (Spravato), administered intranasally, is FDA-approved for treatment-resistant depression but requires enrollment in a Risk Evaluation and Mitigation Strategy (REMS) program with 2-hour post-administration observation. Data in patients aged 65 and older are limited.

## Anxiety Disorders

### Types in Elderly

Generalized anxiety disorder is the most common anxiety disorder in the elderly, characterized by chronic, excessive worry about health, family, finances, and personal safety. Phobic disorders, including fear of falling (ptophobia), agoraphobia, and social anxiety, are common and frequently lead to activity restriction and functional decline. Panic disorder is less common in elderly than in younger adults, and its presentation requires careful exclusion of cardiac and pulmonary causes. Anxiety secondary to medical conditions, including hyperthyroidism, pulmonary embolism, arrhythmias, COPD, and chronic pain, must be identified and the underlying condition treated. Medication-induced anxiety from caffeine, bronchodilators, corticosteroids, thyroid supplements, and withdrawal from benzodiazepines, alcohol, or opioids is another important and treatable cause.

### Treatment

Cognitive behavioral therapy is the first-line treatment for anxiety disorders in the elderly, demonstrating high efficacy for generalized anxiety disorder and phobic disorders. SSRIs are the first-line pharmacotherapy, with sertraline at 25 to 100 mg and escitalopram at 5 to 10 mg being the preferred agents. SNRIs, including duloxetine at 30 to 60 mg and venlafaxine extended-release at 37.5 to 150 mg, are effective alternatives. Buspirone at 5 to 15 mg two to three times daily is non-sedating, carries no dependence liability, and produces no cognitive impairment, but requires 2 to 4 weeks to achieve its effect and has limited efficacy as monotherapy.

Benzodiazepines should be avoided for chronic anxiety management in the elderly as designated by the Beers Criteria. Their use is acceptable only for acute crisis situations, short-term use of 2 weeks or less, or specific situational needs such as MRI claustrophobia. Patients already on chronic benzodiazepines should undergo gradual taper over 6 to 12 weeks with concurrent CBT support to manage withdrawal symptoms and prevent relapse.

<image>A treatment algorithm for late-life depression. Start with "Depression diagnosed (PHQ-9 ≥10 or GDS-15 ≥5 + clinical assessment)." First: "Assess severity and safety — suicidal ideation screening (C-SSRS), psychotic features, functional impact." Branch by severity: MILD → "Psychotherapy (CBT, PST, BA) ± exercise program; reassess in 4-6 weeks." MODERATE → "SSRI (sertraline 25mg or escitalopram 5mg) + psychotherapy; titrate at 4 weeks if partial response." SEVERE → "SSRI + psychotherapy; if psychotic features → SSRI + antipsychotic or ECT; if imminent suicide risk → hospitalize, consider ECT." Show response assessment at 8-12 weeks: "Full remission" → continue 12+ months; "Partial response" → optimize dose, add augmentation (aripiprazole 2-5mg or lithium 300-600mg); "No response" → switch antidepressant class (SNRI, mirtazapine), consider ECT for treatment-resistant. Include a "Red Flags Requiring Urgent Action" box: suicidal ideation with plan, psychotic features (nihilistic delusions), refusal to eat/drink, catatonia → ECT is the most effective intervention. Show a sidebar with medications to AVOID: paroxetine, fluoxetine, TCAs (amitriptyline), benzodiazepines for chronic use.</image>

## Key Clinical Pearls

- Late-life depression often presents as somatic complaints, apathy, and cognitive impairment rather than expressed sadness — "depression without sadness" is a common geriatric phenotype
- The GDS-15 avoids somatic symptom confounding and is specifically designed for elderly — it should be part of every CGA
- Elderly white males have the highest suicide completion rate — always assess suicide risk directly, including access to firearms
- SSRIs cause hyponatremia (SIADH) in elderly, especially when combined with diuretics — check sodium at 2-4 weeks after starting or changing dose
- Paroxetine and fluoxetine should be AVOIDED in elderly — paroxetine is too anticholinergic and fluoxetine has too many drug interactions; sertraline and escitalopram are preferred
- ECT is the most effective treatment for severe, psychotic, and treatment-resistant depression in elderly — it is safe even in advanced age with proper anesthetic management
- Depression in elderly may be a prodrome of dementia — it doubles the risk of subsequent dementia; treat depression but monitor cognition longitudinally

## References
1. Alexopoulos GS. Mechanisms and treatment of late-life depression. *Transl Psychiatry*. 2019;9(1):188.
2. Kok RM, Reynolds CF III. Management of depression in older adults: a review. *JAMA*. 2017;317(20):2114-2122.
3. Lenze EJ, Mulsant BH, Mohlman J, et al. Generalized anxiety disorder in late life: lifetime course and comorbidity with major depressive disorder. *Am J Geriatr Psychiatry*. 2005;13(1):77-80.
4. Blumenfeld M, Levin TT. Late-life depression. *N Engl J Med*. 2024;390:2456-2466.
5. Conwell Y, Van Orden K, Caine ED. Suicide in older adults. *Psychiatr Clin North Am*. 2011;34(2):451-468.